Vassilios Aslanis - Concepedia

Author

Vassilios Aslanis

Novartis (Switzerland)ORCID

Also Known As

V Aslanis, V. Aslanis, Vassilios Aslanis

Publications

486

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Novartis Institutes for BioMedical Research Galecto (Denmark)

About

Vassilios Aslanis is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	72
2	Pharmacology	2	2	42
3	Health Sciences	1	1	30
4	Clinical Pharmacology	1	1	29
5	Clinical Trials	1	1	30

Vassilios Aslanis

Publications

440

Citations

H-Index

Page 1

	Year	Citations
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i> -Mutant Melanoma Jean‐Pierre Delord, Caroline Robert, Marta Nyakas, Clinical Cancer Research	2017	184
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy Mario Campone, H. Cortés-Funes, Daniel Vorobiof, British Journal of Cancer	2006	53
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE) Erin Gaughan, Tom Quinn, Andrew C. Mills, American Journal of Respiratory and Critical Care Medicine	2022	37
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants Vassilios Aslanis, Robert J. Slack, Alison C. MacKinnon, Cancer Chemotherapy and Pharmacology	2023	36
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study Noelle V. Frey, Jun Ho Jang, Jeff Szer, The Lancet Haematology Hematological MalignancyEltrombopag TreatmentMedicineMixed-phenotype Acute LeukemiaHematology	2019	30
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions Kenichi Umehara, Felix Huth, Yi Jin, Drug Metabolism and Personalized Therapy	2019	30
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects Vassilios Aslanis, Kenichi Umehara, Felix Huth, Cancer Chemotherapy and Pharmacology Drug SafetyPharmacologyHealthy Adult SubjectsClinical PharmacologyMultiple Administrations	2019	29
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi, International Journal of Clinical Pharmacology and Therapeutics	2016	14
Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia Mary Beth Wire, Xiaobin Li, Jianping Zhang, Clinical Pharmacology & Therapeutics	2018	14
Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi, Clinical Therapeutics Heart FailureCardiac RepolarizationCardiovascular DiseaseHealthy SubjectsMedicine	2015	13

Page 1